PUBLIC COMPANY
save$ELVNEnliven Therapeutics, Inc.
$ELVN51.20-0.68%Boulder, CO, USupdated 6d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- phase1ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- phase1ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- phase1ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
🐶 Hiring Signal
News
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialA Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.biopharma_dive · 1mo ago
- Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studyPlus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after sa…endpoints · 5mo ago
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 5mo ago
- STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studyA targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.stat · 5mo ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that